Penserra Capital Management LLC Makes New Investment in Charles River Laboratories International, Inc. $CRL

Penserra Capital Management LLC acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,412 shares of the medical research company’s stock, valued at approximately $533,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Patriot Financial Group Insurance Agency LLC raised its position in Charles River Laboratories International by 4.2% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 2,120 shares of the medical research company’s stock worth $332,000 after purchasing an additional 85 shares in the last quarter. DekaBank Deutsche Girozentrale raised its stake in Charles River Laboratories International by 1.2% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,142 shares of the medical research company’s stock worth $1,072,000 after acquiring an additional 86 shares in the last quarter. Resona Asset Management Co. Ltd. lifted its holdings in shares of Charles River Laboratories International by 17.5% during the third quarter. Resona Asset Management Co. Ltd. now owns 584 shares of the medical research company’s stock valued at $86,000 after acquiring an additional 87 shares during the period. WESCAP Management Group Inc. boosted its stake in shares of Charles River Laboratories International by 3.8% in the 2nd quarter. WESCAP Management Group Inc. now owns 2,443 shares of the medical research company’s stock valued at $371,000 after purchasing an additional 89 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D grew its holdings in shares of Charles River Laboratories International by 0.7% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 16,829 shares of the medical research company’s stock worth $2,553,000 after purchasing an additional 109 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Trading Up 2.9%

CRL stock opened at $189.11 on Monday. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $228.88. The company has a market cap of $9.31 billion, a P/E ratio of -121.22, a PEG ratio of 5.67 and a beta of 1.63. The business has a fifty day moving average of $204.33 and a 200-day moving average of $179.96.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Mizuho set a $215.00 price target on shares of Charles River Laboratories International in a research report on Friday, January 9th. Robert W. Baird set a $224.00 price target on Charles River Laboratories International in a research report on Friday, January 9th. Citigroup lifted their price objective on Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a research report on Friday, January 16th. JPMorgan Chase & Co. boosted their price objective on Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. Finally, Evercore raised their target price on Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Ten research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $209.46.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.